The ovarian cancer market has transformed in recent years, driven by the expanding use of PARP inhibitors, antiangiogenic ...

Health Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase ...

EULAR now recommends moving directly to biologic or targeted synthetic disease-modifying antirheumatic drugs if the initial ...

After its $1 billion acquisition by Novartis, Mariana Oncology is expanding its Massachusetts real estate. Biotech's Future - ...